Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

Author:

Nissen Steven E.1,Menon Venu1,Nicholls Stephen J.2,Brennan Danielle1,Laffin Luke1,Ridker Paul3,Ray Kausik K.4,Mason Denise1,Kastelein John J. P.5,Cho Leslie1,Libby Peter3,Li Na6,Foody JoAnne6,Louie Michael J.6,Lincoff A. Michael1

Affiliation:

1. Cleveland Clinic, Cleveland, Ohio

2. Victorian Heart Institute, Monash University, Melbourne, Australia

3. Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

4. Imperial College London, London, United Kingdom

5. University of Amsterdam Academic Medical Center, Amsterdam, the Netherlands

6. Esperion Therapeutics Inc, Ann Arbor, Michigan

Abstract

ImportanceThe effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients without a prior cardiovascular event (primary prevention) have not been fully described.ObjectiveTo determine the effects of bempedoic acid on cardiovascular outcomes in primary prevention patients.Design, Setting, and ParticipantsThis masked, randomized clinical trial enrolled 13 970 statin-intolerant patients (enrollment December 2016 to August 2019 at 1250 centers in 32 countries), including 4206 primary prevention patients.InterventionsParticipants were randomized to oral bempedoic acid, 180 mg daily (n = 2100), or matching placebo (n = 2106).Main Outcome MeasuresThe primary efficacy measure was the time from randomization to the first occurrence of any component of a composite of cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization.ResultsMean participant age was 68 years, 59% were female, and 66% had diabetes. From a mean baseline of 142.2 mg/dL, compared with placebo, bempedoic acid reduced low-density lipoprotein cholesterol levels by 30.2 mg/dL (21.3%) and high-sensitivity C-reactive protein levels by 0.56 mg/L (21.5%), from a median baseline of 2.4 mg/L. Follow-up for a median of 39.9 months was associated with a significant risk reduction for the primary end point (111 events [5.3%] vs 161 events [7.6%]; adjusted hazard ratio [HR], 0.70 [95% CI, 0.55-0.89]; P = .002) and key secondary end points, including the composite of cardiovascular death, MI, or stroke (83 events [4.0%] vs 134 events [6.4%]; HR, 0.64 [95% CI, 0.48-0.84]; P < .001); MI (29 events [1.4%] vs 47 events [2.2%]; HR, 0.61 [95% CI, 0.39-0.98]); cardiovascular death (37 events [1.8%] vs 65 events [3.1%]; HR, 0.61 [95% CI, 0.41-0.92]); and all-cause mortality (75 events [3.6%] vs 109 events [5.2%]; HR, 0.73 [95% CI, 0.54-0.98]). There was no significant effect on stroke or coronary revascularization. Adverse effects with bempedoic acid included a higher incidence of gout (2.6% vs 2.0%), cholelithiasis (2.5% vs 1.1%), and increases in serum creatinine, uric acid, and hepatic enzyme levels.ConclusionsIn a subgroup of high-risk primary prevention patients, bempedoic acid treatment was associated with reduced major cardiovascular events.Trial RegistrationClinicalTrials.gov Identifier: NCT02993406

Publisher

American Medical Association (AMA)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3